The Melanoma Research Alliance (MRA) is the largest private funder of melanoma research. To date, MRA has awarded more than $67 million to make transforming advances in the prevention, diagnosis and staging, and treatment of melanoma, including research in biological causes of carcinogenesis, skin screening, biomarkers, imaging, immunotherapy, molecularly targeted therapy, and combination therapy.Melanoma is the deadliest form of skin cancer, and it is one of the cancers whose incidence is increasing fastest in this country.
Our ultimate goal is to find a cure by funding the most promising melanoma research worldwide that will accelerate progress and improve outcomes for patients and all who are at risk.
In 2007, melanoma touched the lives of Debra and Leon Black when Debra was diagnosed with the disease. With melanoma incidence rising dramatically and survival for those with advanced disease remaining static at less than 15 percent, the Blacks formed MRA under the auspices of the Milken Institute. Thanks to their generous ongoing support, 100% of every donation to MRA goes directly to melanoma research.
Collaboration is at MRA’s core—from the team approaches to research that we fund, to the way we find partners who can help us realize our vision. Our allies are also focused on increasing public knowledge about the seriousness of melanoma and ways to reduce risk and improve early detection.